Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q1 EPS of ($0.15), $0.02 worse than the analyst estimate of ($0.13).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.